Abstract. MicroRNAs (miRNAs/miRs) are a cluster of short non-protein coding RNAs that negatively regulate gene expression, which is involved in fundamental cellular processes, including the response of tumor cells to chemotherapeutic agents. The present study investigated the role of miR-106a in the development of drug resistance in ovarian cancer cells. The expression of miR-106a in the ovarian cancer OVCAR3 cell line and the cisplatin (CDDP)-resistant ovarian cancer OVCAR3/CIS cell line was detected using stem-loop quantitative (q)PCR. The OVCAR3 and OVCAR3/CIS cells were transfected with mimics or inhibitors of miR-106a or with negative control (NC) RNA using lipofectamine 2000. Luciferase reporter assays were used to determine whether PDCD4 was a direct target of miR-106a in the OVCAR3 cells. The expression levels of the PDCD4 proteins were assessed using qRT-PCR and western blotting, respectively. Drug sensitivity was analyzed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, while apoptosis was determined by fluorescence-activating cell sorting analysis. The expression levels of miR-106a were upregulated in the CDDP-resistant ovarian cancer OVCAR3/CIS cell line compared with the parental OVCAR3 cell line. However, the PDCD4 protein levels were decreased in the OVCAR3/CIS cells compared with the OVCAR3 cells. The luciferase reporter assays revealed that PDCD4 was a direct miR-106a target in the OVCAR3 cells. Transfection of the OVCAR3/CIS cells with inhibitors of miR-106a enhanced the sensitivity of the OVCAR3/CIS cells to CDDP and increased CDDP-induced apoptosis. The expression of the PDCD4 protein and the sensitivity to CDDP was decreased in the OVCAR3 cells that were transfected with the mimics of miR-106a. The knockdown of PDCD4 expression using PDCD4-specific siRNAs in the OVCAR3 cells demonstrated that PDCD4 is a key signaling molecule in OVCAR3 cell CDDP-induced resistance. miR-106a may be involved in the development of drug resistance and the regulation of PDCD4 expression, at least in part, by modulating CDDP-induced apoptosis in ovarian cancer cells.

Introduction

Ovarian cancer is the leading cause of mortality from gynecological malignancy and the fifth most common cause of cancer-related mortality in females (1). Currently the standard treatment for advanced-stage ovarian cancer is primary cytoreductive surgery, followed by platinum and paclitaxel combination chemotherapy. Although there have been improvements, the long-term survival rate remains poor due to the emergence of drug resistance. The majority of ovarian cancer patients who are initially sensitive to chemotherapeutic agents will eventually relapse, and in a number of cases, acquired resistance leaves no available curative treatments (2). Emerging evidence indicates that a deregulated apoptosis pathway is a major contributor to tumor initiation and the progression and development of acquired resistance to anti-cancer therapies (3).

MicroRNAs (miRNAs/miRs) are a class of non-coding RNAs that regulate gene expression (4) by repressing mRNA translation or cleaving target mRNA. MicroRNAs play a role in growth control, and a relationship between miRNAs and cancer is anticipated. Furthermore, microRNAs that are involved in specific networks, including apoptosis, proliferation or receptor-driven pathways, may affect the response to targeted therapies or to chemotherapy. microRNAs are differentially expressed in chemosensitive and chemoresistant cells (5). miR-98, -21 and -125b have been shown to potentiate chemoresistance (6-8). Sorrentino et al investigated the role of microRNAs in drug-resistant ovarian cancer cells (9). miR-125b was shown to be downregulated in the A2780/TAX cells and upregulated in the other resistant cell lines. Yang et al investigated microRNA expression profiles in cisplatin (CDDP)-resistant ovarian cancer cells and identified that miR-106a was upregulated in
propidium iodide (PI) staining was performed to induce apoptosis. The transfection of the miR-106a mimic, miR-106a antisense ensure that they would reach 30% confluence the following day. Cell transfection. Each sample was run in triplicate. qRT-PCR was performed as described previously (14). 

Quantitative reverse transcription PCR (qRT-PCR). To analyze the miR-106a expression levels, RNA was extracted from the cells. The stem-loop qRT-PCR assay was used to quantify the miRNA expression levels as described previously (12). The qRT-PCR primers were as follows: miR-106a RT primer, 5'-GTCGTATCCAGTGCAGGGTGACTTCGAGGTATTCGACCTGATCGACTACCTACCT-3'; miR-106a PCR primer sense, 5'-CGCAAAGTGCTTACAGTGCA-3' and antisense, 5'-GTGCGAGGGTCCGAGGT-3'; U6 RT primer, 5'-CTCAACTTGTTGTCGAGTGGGACAAA-3'; and U6 PCR primer sense, 5'-CGCAAAAGTGCTTACAGTGCA-3' and antisense, 5'-AACGGCTTCAGGAATTTGCCT-3'. The SYBR Premix Ex Taq™ kit (Takara, Dalian, China) was used according to the manufacturer's instructions, and qRT-PCR was performed and analyzed using the CFX-96 Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). The PCR conditions were 95°C for 3 min, followed by 40 cycles of 95°C for 30 sec, 58°C for 30 sec and 72°C for 30 sec. The expression levels of miR-106a were normalized with reference to the expression levels of U6 snRNA, and the fold changes were calculated by $2^{-\Delta\Delta Ct}$ (13). For PDCD4 mRNA detection, qRT-PCR was performed as described previously (14). Each sample was run in triplicate.

Cell transfection. The cells were seeded in six-well plates to ensure that they would reach 30% confluence the following day. The transfection of the miR-106a mimic, miR-106a antisense oligonucleotide (ASO) or negative control (NC) oligonucleotide was performed using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instructions. Following 48 h of transfection, the cells were harvested and processed for further analysis. 

Luciferase reporter assays. The full-length 3' UTR of PDCD4 was amplified and cloned into the XbaI-site of pGL3 (Promega, Madison, WI, USA), checked for orientation, sequenced, and named Luc-PDCD4Wt. The site-directed mutagenesis of the miR-21 target site in the PDCD4-3'UTR was performed using the QuikChange Mutagenesis kit (Stratagene, Heidelberg, Germany), with Luc-PDCD4Wt as a template. For the reporter assays, the OVCAR3 cells were transfected with wild-type (WT) or mutant reporter plasmids and with miR-106a mimics using lipofectamine 2000 (Invitrogen). The reporter assays were performed at 48 h post-transfection using the Dual-luciferase assay-system (Promega) and normalized for transfection efficiency by cotransfected Renilla-luciferase.

Materials and methods

Cell culture. The human ovarian cancer OVCAR3 cell lines were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The CDDP-resistant ovarian cancer OVCAR3/CIS cell line was induced using progressive concentrations of CDDP as described previously (11). The OVCAR3 and CDDP-resistant OVCAR3/CIS cell lines were cultured in PRMI-1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco), 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified incubator with 5% CO₂ at 37°C. The OVCAR3/CIS cells were alternately fed with medium containing 7.5 µg/ml CDDP and were regularly tested for the maintenance of drug-resistance. The CDDP-resistant cell line was maintained in drug-free medium for 1 week prior to the follow-up experiments.

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The cells were seeded into 96-well plates at 5x10³ cells/well, allowed to grow overnight and then treated with various concentrations of CDDP (QiLu Pharmaceutical, Jinan, China). Following 24 h of treatment, 20 µl 5 mg/ml MTT reagent (Sigma-Aldrich, St. Louis, MO, USA) was added and incubated in the dark for 4 h. The viability of the treated cells was calculated from the average OD 490 values compared with that of the untreated cells. Each treatment was carried out in triplicate.

Western blot assay. The extraction and detection of the proteins was performed as described previously (15). The protein samples were separated by sodium dodecyl sulfate-polyacylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The membranes were then blocked with 1% BSA in TBST containing 0.1% Tween-20 for 1 h. The filters were then incubated overnight at 4°C with rabbit mAb against PDCD4, cleaved caspase-3, -8 and -9 (1:1,000; Cell Signaling Technology, Beverly, MA, USA) and mouse mAb GAPDH (1:2,000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Immunoblotting was performed by incubating the membranes at 4°C overnight followed by the goat anti-mouse secondary antibodies (Zhongshan Biotechnology Ltd., Co., Beijing, China) conjugated for 1 h at room temperature. Subsequent to washing the membranes, antibody binding was detected using an enhanced chemiluminescence kit (Pierce, Rockford, IL, USA). All western blot experiments were repeated at least three times.

Knockdown of PDCD4 expression mediated by siRNA. The siRNAs targeting PDCD4 and non-specific NC were purchased from Ambion (Austin, TX, USA). The siRNAs were transfected into the OVCAR3 cells using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Following the treatment, the cells were harvested for the subsequent experiments. The experiment was repeated three times.

Apoptosis assay. To quantify CDDP-induced apoptosis, annexin V/propidium iodide (PI) staining was performed
Expression of PDCD4 correlates with the cytotoxic activity of CDDP in ovarian cancer cell lines. To determine the effect of PDCD4 expression on the sensitivity of ovarian cancer cells to CDDP, the expression of PDCD4 was measured in the OVCAR3 and OVCAR3/CIS cells using qRT-PCR and western blot analysis. As shown in Fig. 1A-C, PDCD4 expression was low in the OVCAR3/CIS cells and high in the OVCAR3 cells. The results from the MTT assays revealed that the OVCAR3 cells with relatively high levels of PDCD4 expression were more sensitive to CDDP compared with the OVCAR3/CIS cells (Fig. 1D). These results indicate that PDCD4 expression may be associated with a high sensitivity to CDDP in ovarian cancer cell lines. The expression levels of miR-106a in the OVCAR3 and OVCAR3/CIS cells were detected using qRT-PCR. It was shown that miR-106a had an average 7.8-fold higher expression level in the OVCAR3 cells compared with the NC (Fig. 2A). The overexpression of miR-106a was associated with the significantly increased survival rate of the OVCAR3 cells (Fig. 2B). The OVCAR3/CIS cells were transfected with either the miR-106a ASO or an NC, and were subsequently incubated with various doses of CDDP. Conversely, transfection with 100 pmol miR-106a inhibitors effectively reduced miR-106a expression and resulted in a significantly lower survival rate in the OVCAR3/CIS cell lines (Fig. 2C and D).

PDCD4 is a target of miR-106a. PDCD4 protein expression was significantly downregulated in the OVCAR3/CIS cells compared with the parental OVCAR3 cells. However, it remains unclear whether the downregulation of PDCD4 induced by the overexpression of miR-106a is involved in the resistance of the OVCAR3 cells to CDDP. Computer-aided algorithms were obtained from TargetScan and the potential binding site of miR-106a (position 854-860) was predicted to be the PDCD4 3’-UTR. As shown in Fig. 3A, transfection of the miR-106a mimics in the OVCAR3 cells with the WT 3’-UTR (pLuc-PDCD4 3’-UTR-wild) vector significantly decreased the luciferase activity compared with the control inhibitor (P<0.05). However, transfection of the miR-106a mimics in the OVCAR3 cells with the mutant 3’-UTR (pLuc-PDCD4 3’-UTR-mut) vector showed no effect on lucif-
LI et al: CISPLATIN SENSITIVITY MODULATED BY miR-106a

Figure 2. Correlation between miR-106a and cisplatin resistance in ovarian cancer cells. (A) The levels of miR-106a in the OVCAR3 cells that were transfected with the miR-106a mimics or NC. (B) Overexpression of miR-106a was associated with the significantly increased survival rate of the OVCAR3 cells. (C) The levels of miR-106a in the OVCAR3/CIS cells that were transfected with the miR-106a inhibitors or NC. (D) Downregulation of miR-106a was associated with the significantly increased survival rate of the OVCAR3/CIS cells. miR, microRNA; NC, negative control; ASO, antisense oligonucleotide.

Figure 3. PDCD4 was a target of miR-106a. (A) Luciferase reporter assays confirmed that PDCD4 was a direct miR-106a target in the OVCAR3 cells. (B and C) The expression levels of PDCD4 protein in the OVCAR3/CIS cells that were transfected with the miR-106a inhibitor were significantly increased compared with that in the OVCAR3/CIS cells that were transfected with the control inhibitor. (D and E) The expression levels of PDCD4 protein in the OVCAR3 cells that were transfected with the miR-106a mimic were significantly increased compared with that in the OVCAR3 cells that were transfected with the control inhibitor. miR, microRNA; NC, negative control; ASO, antisense oligonucleotide.

Regardless of the miR-106a mimic, the luciferase activity compared with the control inhibitor (P>0.05). Furthermore, the expression levels of the PDCD4 protein in the OVCAR3/CIS cells that were transfected with the miR-106a inhibitor were significantly increased compared with that of the OVCAR3/CIS cells that were transfected with the control inhibitor (P<0.05; Fig. 3B and C). Conversely, the expression levels of the PDCD4 protein in the OVCAR3 cells that were transfected with the miR-106a mimic were significantly increased compared with that in the OVCAR3 cells that were transfected with the control inhibitor (P<0.05; Fig. 3D and E).
increased compared with that of the OVCAR3 cells that were transfected with the control inhibitor (P<0.05; Fig. 3D and E). All these data indicated that PDCD4 was post-transcriptionally regulated by miR-106a in the OVCAR3 cells.

**PDCD4 is a key signaling molecule in induced CDDP resistance in OVCAR3 cells.** To further confirm the effect of PDCD4 on the chemosensitivity of ovarian cancer cells, PDCD4 expression was knocked down using PDCD4-specific siRNAs in the OVCAR3 cells. As shown in Fig. 4A-C, the PDCD4-specific siRNAs markedly inhibited the expression of the PDCD4 mRNA by 70% and the PDCD4 protein by 80%, whereas the NC had no significant effect on PDCD4 expression. The PDCD4 siRNAs significantly increased cell viability compared with the cells that were treated with the NC (P<0.05; Fig. 4D). This indicated that the downregulation of PDCD4 enhanced the resistance to CDDP. The PDCD4 siRNAs and the scrambled siRNA-transfected OVCAR3 cells were analyzed using FCM to determine cell apoptosis. The PDCD4 siRNAs were identified to decrease the level of CDDP-induced apoptosis in the OVCAR3 cells. (P<0.05; Fig. 4E) To further examine the particular apoptotic pathways by which PDCD4 promotes CDDP-induced apoptosis, the expression of several apoptosis-related proteins was measured. As shown in Fig. 4F, treatment with the PDCD4 siRNAs decreased the expression of cleaved caspase-3 and caspase-8 in the OVCAR3 cells compared with the OVCAR3 cells that were treated with the NC.

**Discussion**

Platinum-based combination chemotherapy is the most widely used method in the treatment of ovarian cancer (16). However, due to resistance, the method often fails to cure patients. Therefore, the reversal of platinum resistance in ovarian cancer and increased sensitivity to platinum-based chemotherapy drugs are crucial issues.

miRNAs are a growing class of small, non-coding RNAs that regulate gene expression by targeting mRNAs to cause translational repression and/or degradation. A large number of miRNAs have been identified as deregulated in various types of human malignancy. Increasing evidence indicates that the deregulation of miRNAs has been frequently observed in cell proliferation, differentiation, apoptosis, metastasis and drug resistance (17-20). The mechanisms responsible for the chemotherapeutic resistance by miRNAs have not been clearly identified. To date, several miRNAs, including miR-451, -21, -214, -23a and -141, have been reported to be involved in the process of CDDP resistance in various tumors (21-23). Based on these findings, Fu et al (11) performed global miRNA expression profiling in human ovarian CDDP-resistance and parental cancer cells, and identified that miR-15a, -19a, -21, -204, -93 and -96 were upregulated and that miR-22 and -489 were downregulated. The present study identified that miR-106a was overexpressed 2.7-fold in the CDDP-resistant OVCAR3/CIS cells compared with the corresponding CDDP-sensitive parental cell line, and the subsequent qRT-PCR experiment confirmed this result. Knockdown of miR-106a enhanced CDDP chemosensitivity in the CDDP-resistant OVCAR3/CDDP cells, while the ectopic expression of miR-106a caused the OVCAR3 cells to be resistant to CDDP-induced apoptosis.

Numerous miR-106a targets have been predicted by TargetScan, including PDCD4. The overexpression of PDCD4 has been reported to increase the sensitivity to CDDP and paclitaxel, but not to etoposide or 5-fluourouracil in human prostate cancer PC3 cells (24). Consistent with this finding, the present study demonstrated that PDCD4 is a target of miR-106a and that it plays a role in CDDP resistance in the OVCAR3 cell line. Furthermore, knockdown of PDCD4 significantly increased the cell survival rate and had an overall effect that was similar to miR-106a overexpression. To the best of our knowledge, this is the first study to describe an association between miR-106a, PDCD4 expression and drug resistance in
CDDP-treated OVCR3 cells. The loss or reduction of PDCD4 expression may be a reason for chemoresistance in ovarian cancer, and the restoration of PDCD4 expression may reverse the resistance of ovarian cancer to chemotherapy. To date, the mechanism by which PDCD4 enhances chemosensitivity remains unclear. Apoptosis in hepatocellular carcinoma was induced by PDCD4 through mitochondrial events and the caspase cascade, including increases in cytosolic cytochrome c and mitochondrial Bax and a reduction in procaspase-3, -8, and -9. The present results revealed that the combination of PDCD4 with CDDP markedly elevated the expression of cleaved caspase-3 and -8. Taken together, the data indicated that PDCD4 promoted CDDP-induced apoptosis mainly through the death receptor-mediated pathway.

In summary, the present study demonstrated that the enhancement of miR-106a expression contributes to the generation of CDDP-resistant ovarian cancer cells, partly by targeting PDCD4. PDCD4 promoted CDDP-induced apoptosis mainly through the death receptor-mediated pathway. The results provide evidence that miR-106a may potentially be used as a predictor of the chemotherapy response in ovarian cancer and is a promising therapeutic target in the treatment of this disease.

References

1. Ehlén A, Brennan DJ, Nodin B, et al: Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med 8: 78, 2010.
2. Weinberg LE, Rodriguez G and Hurteau JA: The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. J Surg Oncol 101: 334-343, 2010.
3. Johnstone RW, Rueli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002.
4. Petrocca F and Lieberman J: Micromanipulating cancer: microRNA-based therapeutics? RNA Biol 6: 335-340, 2009.
5. Boren T, Xiong Y, Hakam A, et al: MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 113: 249-255, 2009.
6. Hebert C, Norris K, Schepker MA, Nikitakis N and Sauer JJ: High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 6: 5, 2007.
7. Moriyma T, Ohuchida K, Mizumoto K, et al: MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 8: 1067-1074, 2009.
8. Zhou M, Liu Z, Zhao Y, et al: MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285: 21496-21507, 2010.
9. Sorrentino A, Liu CG, Addario A, Peshche C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111: 478-486, 2008.
10. Yang L, Li N, Wang H, Jiu X, Wang X and Luo J: Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep 28: 592-600, 2012.
11. Fu X, Tian J, Zhang L, Chen Y and Hao Q: Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 586: 1279-1286, 2012.
12. Chen C, Ridzon DA, Broomer AJ, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acid Res 33: e179, 2005.
13. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
14. Li J, Fu H, Xu C, et al: miR-183 inhibits TGF-beta-induced apoptosis by downregulation of microRNA expression in human hepatocellular carcinoma cells. BMC Cancer 10: 354, 2010.
15. Wei ZT, Zhang X, Wang XY, et al: PDCD4 inhibits the malignant phenotype of ovarian cancer cells. Cancer Sci 100: 1408-1413, 2009.
16. Adams G, Zekri J, Wong H, Walking J and Green JA: Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy? J Biol Chem 285: 1459-1467, 2010.
17. Amaral JD, Xavier JM, Steer CJ and Rodrigues CM: Targeting the p53 pathway of apoptosis. Curr Pharm Des 16: 2493-2503, 2010.
18. Dykxhoorn DM: MicroRNAs and metastasis: little RNAs go a long way. Cancer Res 70: 6401-6406, 2010.
19. Garg M: MicroRNAs, stem cells and cancer stem cells. World J Stem Cells 4: 62-70, 2012.
20. Hummel R, Hussein DJ and Haier J: MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 46: 298-311, 2010.
21. Yu ZW, Zhong LP, Ji T, Zhang P, Chen WT and Zhang CP: MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 46: 317-322, 2010.
22. Hummel R, Watson DI, Smith C, et al: Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. Mol Cancer Res 8: 1343-1351, 2010.
23. Hamano R, Miyata H, Yamasaki M, et al: miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res 17: 3029-3038, 2011.
24. Jansen AP, Camalier CE, Stark C and Colburn NH: Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther 3: 103-110, 2004.